Inpatient · Outpatient · Remote

Strategy for
Providers.

We work with health systems, medical groups, alternative sites of care (ASCs, home, remote, etc.), pharmacy, and new models (primary care, oncology, etc.). We focus on strategy at the local and system levels in areas such as value-based care, local market competitiveness, growth (geography, channel, adjacent services), innovation, and corporate development including PE partnerships.

FEATURED PERSPECTIVE

  • Payers , 
  • Providers , 
  • Institutional

Kidney transplantation, improved but still a significant missed opportunity

In order to make a more immediate and significant impact on dialysis and kidney waitlist, OPOs need to ensure that significantly more potential donors are identified, and all necessary steps are taken to ensure that a potential donor becomes an actual organ donor.

Read the analysis →

"OPOs may be able to realize much greater donation rates and get patients off of dialysis and off of the kidney waitlist earlier"

— Recon analysis

Survivorship Is Expanding Cancer Care — How Are Oncology Providers Responding?

  • Providers , 
  • Digital
Survivorship care is increasingly pivotal to cancer care delivery and …

Read more

AJMC: More frequent visits to primary care can save net $30-40 PMPM for top 20% highest risk commercial members

  • Payers , 
  • Providers
A new AJMC study from consulting firm Recon Strategy is the first to s…

Read more

Kidney transplantation, improved but still a significant missed opportunity

  • Payers , 
  • Providers , 
  • Institutional
In order to make a more immediate and significant impact on dialysis and kidney waitlist, OPOs need to ensure that significantly more potential donors are identified, and all necessary steps are taken to ensure that a potential donor becomes an actual organ donor.

Read more

SELECTED CASE STUDIES

How we've helped Providers

Representative engagements, anonymized. Each pairs deep sector knowledge with rigorous, structured analysis.

Urgent care acquisition assessment

A large healthcare provider was weighing entry into urgent care through acquisition and needed to know what a target chain was actually worth to them.

Urgent care M&A valuation

Molecular diagnostics growth strategy

A molecular diagnostics developer had more new-test opportunities than it could fund and no shared view of which it was equipped to win or whether the economics could work.

New test portfolio prioritization

Medicare Advantage channel strategy

A personal care platform faced a payer market that was growing fast but buying in two incompatible ways and needed to know which model to build its sales approach around.

Payer partnership economics